Karuna Therapeutics

Karuna Therapeutics

Pushing the boundaries of neuroscience to transform the treatment of mental illness.

Founded 2009

Boston, United States 192 employees Private Equity Total: $15.60B Biopharma, Health Care +1

Karuna Therapeutics, a biopharmaceutical company founded in 2009, is making waves in the healthcare industry with its groundbreaking approach to treating mental illness. With the slogan "Pushing the boundaries of neuroscience to transform the treatment of mental illness," Karuna Therapeutics has garnered significant attention. In March 2023, the company received a remarkable $460.00M Post-IPO Equity investment, marking a pivotal moment for its growth and development. Notably, Karuna Therapeutics recently became a part of Bristol Myers Squibb, a move that signifies a new chapter in the company's journey of transforming the lives of patients with neurological and neuropsychiatric diseases. Through this partnership, the company is poised to amplify its impact and reach, positioning itself as a key player in the biopharma and healthcare sectors. The company's relentless commitment to pushing the boundaries of neuroscience sets it apart in the industry, promising innovative solutions to addressing mental health challenges. With its headquarters based in the United States, Karuna Therapeutics continues to drive forward, leveraging its expertise and resources to create meaningful change in the field of mental healthcare. For more information on the company's ongoing endeavors and its collaboration with Bristol Myers Squibb, visit their website at www.bms.com.

Funding Stage	Amount	Investors	Lead Investors	Date
Private Equity	$14.00B	1	Bristol Myers Squibb	15 Jan 2025
Post IPO Equity	$460.00M	-		21 Mar 2023
Post IPO Equity	$750.00M	-		09 Aug 2022
Post IPO Equity	$270.00M	-		01 Mar 2021
Series B	$68.00M	10	Arch Venture Partners, Pivotal bioVenture Partners +8	18 Mar 2019
Series A	$42.00M	4	Arch Venture Partners, Wellcome Trust +2	02 Aug 2018
Grant	$8.00M	1	Wellcome Trust	19 Jun 2018
Debt Financing	$600.00K	-		09 Jun 2011

Funding Stage

Amount

Investors

Lead Investors

Date

Private Equity

$14.00B

Bristol Myers Squibb

15 Jan 2025

Post IPO Equity

$460.00M

21 Mar 2023

Post IPO Equity

$750.00M

09 Aug 2022

Post IPO Equity

$270.00M

01 Mar 2021

Series B

$68.00M

Arch Venture Partners, Pivotal bioVenture Partners +8

18 Mar 2019

Series A

$42.00M

Arch Venture Partners, Wellcome Trust +2

02 Aug 2018

Grant

$8.00M

Wellcome Trust

19 Jun 2018

Debt Financing

$600.00K

09 Jun 2011

FAQ About Karuna Therapeutics

Pushing the boundaries of neuroscience to transform the treatment of mental illness.

Karuna Therapeutics was founded in 2009.

Karuna Therapeutics is headquartered in Boston, United States.

Karuna Therapeutics operates in Biopharma, Health Care and Health and Wellness. Its work centres on neuroscience, biopharmaceutical, treatment development and psychiatric drugs.

Karuna Therapeutics has approximately 192 employees.

Karuna Therapeutics has completed 8 funding rounds, raising a total of $15.60B. The latest funding stage is Private Equity.

Top alternatives and competitors to Karuna Therapeutics include Newron Pharmaceuticals SpA, Palatin Technologies, Zhimeng Biopharma, Cybin Inc, Neuronetics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Karuna Therapeutics and Newron Pharmaceuticals SpA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Karuna Therapeutics

Funding Rounds & Investors (8)

Latest News

Karuna Therapeutics Alternatives & Competitors

FAQ About Karuna Therapeutics